恩替卡韦联合干扰素治疗慢性乙肝对患者血清纤维化指标的影响

发布时间：2018-03-24 17:46

  本文选题：慢性乙肝　切入点：恩替卡韦　出处：《基层医学论坛》2016年35期

【摘要】：目的研究恩替卡韦与干扰素联合治疗慢性乙肝对患者血清纤维化指标的影响。方法将我院收治的400例慢性乙肝患者随机分为对照组200例,使用恩替卡韦治疗;治疗组200例,采用恩替卡韦与干扰素联合治疗。观察2组患者治疗前后血清纤维化指标与肝功能指标变化。结果治疗后,2组患者肝功能指标、血清纤维化指标均降低,但对照组患者ALT、TBi L水平及LN、Ⅳ-C、HA、PCⅢ水平下降程度均低于治疗组,差异有统计学意义(P0.05)。结论采用恩替卡韦与干扰素联合治疗慢性乙肝,可增强抗病毒效果,调节肝功能、血清纤维化指标水平,减缓肝硬化发展进程。
[Abstract]:Objective to study the effect of entecavir combined with interferon on serum fibrosis in patients with chronic hepatitis B. methods 400 patients with chronic hepatitis B in our hospital were randomly divided into control group (n = 200) and treatment group (n = 200). The changes of serum fibrosis index and liver function index before and after treatment were observed. However, the levels of alt TBi L and LN, 鈪，

本文编号：1659359